Reacción #307151

ord-a7a5ae3ca37d4f28ba7a471fa1a5f307

Ecuación de reacción

COCc1cc(-c2nc(-c3cccc(C(=O)Cl)c3)no2)ccc1-c1ccccc1C
3-{5-[2-(methoxymethyl)-2′-methylbiphenyl-4-yl]-1,2,4-oxadiazol-3-yl}benzoyl chloride
CNCC(=O)OC.Cl
sarcosine methyl ester hydrochloride
COCc1cc(-c2nc(-c3cccc(C(=O)N(C)CC(=O)OC)c3)no2)ccc1-c1ccccc1C
title compound
COCc1cc(-c2nc(-c3cccc(C(=O)N(C)CC(=O)OC)c3)no2)ccc1-c1ccccc1C
Methyl N-(3-{5-[2-(methoxymethyl)-2′-methylbiphenyl-4-yl]-1,2,4-oxadiazol-3-yl}benzoyl)-N-methylglycinate

Condiciones de reacción

Condiciones detalladas
See reaction.notes.procedure_details.

Tratamiento posterior

  1. 1
    OtroThe title compound was prepared following procedure

Procedimiento

The title compound was prepared following procedure described in example 121 starting from 3-{5-[2-(methoxymethyl)-2′-methylbiphenyl-4-yl]-1,2,4-oxadiazol-3-yl}benzoyl chloride, prepared as in example 130, and sarcosine methyl ester hydrochloride. The title compound was obtained as a sticky solid. 1H NMR: (DMSO-d6, 300 MHz) δ 8.42 (brs, 1H), 8.28 (m, 2H), 8.17 (m, 1H), 7.61 (m, 2H), 7.34-7.22 (m, 4H), 7.12 (m, 1H), 4.32 (s, 1H), 4.22 (s, 1H), 3.80 (m, 3H), 3.32 (s, 3H), 3.1 (m, 3H). LC/MS (Method B): 486.2 (M+H)+ no (M−H)−. HPLC (Method A) Rt: 5.66 min (purity: 98.5%).

Fuente

DOI: 10.6084/m9.figshare.5104873.v1Patente: US08202865B2uspto-grants-2012_06